180 Life Sciences (NASDAQ: ATNF) today announced its engagement of Kinexum, a strategic advisory firm, to support the company in submitting a Marketing Authorisation Application (“MAA”) for adalimumab to treat progressive early-stage Dupuytren’s disease. According to the announcement, the MAA will be submitted to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (“MHRA” or “Agency”). As part of the application, 180 Life Sciences expects to request a Conditional Marketing Authorisation (“CMA”), which assures the agency that long term outcome data will be forthcoming. Including costs associated with the Kinexum agreement, the company anticipates that it will spend approximately $900,000 to $1,000,000 in the next three quarters for activities associated with the MHRA filing and other regulatory preparations.
To view the full press release, visit https://ibn.fm/sNsYA
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company driving groundbreaking studies into clinical programs, which are seeking to address major unmet medical needs. The company’s focus is a novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor).
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
